Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ARHGEF7
REST API REST API
Homo sapiens
ARHGEF7 is differentially expressed in 311 experiments: 168 organism parts: bone marrow, liver, ... (166 more);, 216 disease states: normal, acute promyelocytic leukemia, ... (214 more);, 108 cell types 429 cell lines 35 compound treatments and 80 other conditions.
Synonyms P50, PIXB, BETA-PIX, KIAA0142, P50BP, Nbla10314, P85SPR, P85, DKFZp761K1021, P85COOL1, DKFZp686C12170, PAK3, COOL1
Orthologs Arhgef7 (Rattus norvegicus)   Arhgef7 (Mus musculus)   ARHGEF7 (Bos taurus)   arhgef7a (Danio rerio)   arhgef7b (Danio rerio)   ARHGEF7 (Gallus gallus)   ENSCING00000001710 (Ciona intestinalis)   rtGEF (Drosophila melanogaster)   CDC24 (Saccharomyces cerevisiae)   arhgef7 (Xenopus laevis)   ARHGEF7 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, negative regulation of epidermal growth factor receptor signaling pathway, protein binding, apoptosis, epidermal growth factor receptor signaling pathway, intracellular, positive regulation of apoptosis, regulation of Rho protein signal transduction, guanyl-nucleotide exchange factor activity, small GTPase mediated signal transduction, regulation of small GTPase mediated signal transduction, Rho guanyl-nucleotide exchange factor activity, nervous system development, signal transduction, induction of apoptosis by extracellular signals, nerve growth factor receptor signaling pathway, intracellular signal transduction
InterPro Term SH3_domain, Pleckstrin_homology, DH-domain, SH3_2, CH-domain, SH3_3
UniProt Accession Q5ZEZ2, Q5ZEZ3, C9JAD7, C9JDI6, Q14155, Q5W9H1, B1ALK7, B1ALK5, B1ANY6, E7ENL8, E7EU80, E7EUY6, E9PDQ5, B7Z6D9, B7Z6G2
Search EB-eye ENSG00000102606
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-19639, E-GEOD-4717, E-GEOD-2450, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
A549
2
E-GEOD-3202, E-GEOD-6013
HCC2157
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
T84
2
E-GEOD-1474, E-MTAB-37
423 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (50 experiments)

Factor Value U/D Experiments
CD14+ monocyte
3
2
E-AFMX-5, E-TABM-145
CD34+
2
E-TABM-145, E-AFMX-5
2
2
E-TABM-145, E-TABM-130
fibroblast
2
E-GEOD-3920, E-GEOD-26672
stromal cell
1
2
E-GEOD-1460, E-MEXP-2034, E-GEOD-10797
CD8+ naive CD8 T cell
1
E-TABM-40
102 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, ... (70 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
3
E-GEOD-2466, E-MTAB-37, E-GEOD-6691
acute promyelocytic leukemia
1
3
E-GEOD-1729, E-MTAB-62, E-GEOD-96, E-GEOD-995
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
colon carcinoma
2
E-MTAB-62, E-MTAB-37
210 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-1417, ... (24 experiments)

Factor Value U/D Experiments
none
1
7
E-MEXP-1958, E-GEOD-5824, E-GEOD-412, E-GEOD-2803, E-GEOD-995, ... (8 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
4OH-tamoxifen
1
E-GEOD-2292
rapamycin
1
E-GEOD-5824
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
no estradiol
1
E-GEOD-20081
29 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
36
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-19348, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-GEOD-2666, E-MTAB-62

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-GEOD-361, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-TABM-868, ... (14 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-7011, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-MEXP-1648, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-MEXP-2177

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.419 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM